PhRMA Announces Major Actions as Part of Industry’s Commitment to American Patients and Workers

Posted on Mon/29/SeptemberTue/30/September by AZBio

WASHINGTON, D.C. (September 29, 2025) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced three major actions as part of the biopharmaceutical industry’s commitment to American patients and workers.

PhRMA member companies are making historic investments in U.S.-based manufacturing and infrastructure, providing financial assistance to millions of insured and underinsured patients who have been failed by a broken health insurance system, and announcing a new website that will simplify access to manufacturer direct purchase and patient assistance resources. Continue reading→

A new era in ASU X-ray science officially begins

Posted on Sun/28/SeptemberSun/28/September by AZBio

First X-ray machine’s commissioning milestone marks start of research phase for one-of-a-kind labContinue reading→

The Value of Managing Valley Fever for Arizona Stakeholders

Posted on Sat/27/SeptemberSat/27/September by AZBio

Managing Valley fever starts with awareness. Since there’s no surefire way to avoid getting Valley fever in Arizona, knowledge is everyone’s best defense — but awareness needs a community effort. Continue reading→

Governor Katie Hobbs Appoints Virginia “Ginny” Rountree to lead AHCCCS

Posted on Fri/26/SeptemberFri/26/September by AZBio

Governor Katie Hobbs Appoints Virginia “Ginny” Rountree to lead AHCCCSContinue reading→

Administration Announces a 100 Percent Potential Tariff on Branded or Patented Pharmaceuticals

Posted on Fri/26/SeptemberFri/26/September by AZBio

President Trump posted the following on Truth Social on Thursday, September 25, 2025: “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. “IS BUILDING” will be defined as, “breaking ground” and/or “under construction.” There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. Thank you for your attention to this matter!” Source: https://truthsocial.com/@realDonaldTrump/115267512131958759 Continue reading→

Online Resource Spotlights A New Era of Biopharmaceutical Innovation

Posted on Fri/26/SeptemberSat/27/September by AZBio

The biopharmaceutical industry is on the brink of unprecedented breakthroughs, with the potential to revolutionize health care, reduce the burden of disease and create a healthier future for all. Innovation.org puts biopharmaceutical innovation in the spotlight.

Continue reading→

Next up for Section 232 Investigations – Medtech

Posted on Thu/25/SeptemberThu/25/September by AZBio

The US Commerce Department disclosed on September 24, 2025 that new “Section 232” investigations into the import of personal protective equipment, medical items, robotics and industrial machinery were opened on September 2, 2025 but not previously disclosed.Continue reading→

U of A and UNM win joint $43.6M NIH award to help turn clinical research into practical medicine

Posted on Tue/23/SeptemberTue/23/September by AZBio

The CTSA grant, the largest infrastructure and training award from the NIH, supports the translation of research discoveries into improved patient care.

Continue reading→

MiiHealth AI to Collaborate with one of the leading Health Systems in the United States to advance DAINA, its AI Agent for Streamlining Patient Intake

Posted on Mon/22/SeptemberMon/22/September by AZBio

Phoenix, Ariz., MiiHealth AI, an emerging leader in agentic AI for healthcare, has announced it has entered into a know-how agreement with Mayo Clinic. This collaboration aims to revolutionize patient intake, streamline provider workflows, and enhance care quality.Continue reading→

NIH Launches $50M Autism Data Science Initiative to Unlock Causes and Improve Outcomes

Posted on Mon/22/SeptemberMon/22/September by AZBio

The National Institutes of Health has launched the Autism Data Science Initiative (ADSI) <https://dpcpsi.nih.gov/autism-data-science-initiative>, a landmark research effort that will harness large-scale data resources to explore contributors to the causes and rising prevalence of autism spectrum disorder. More than $50 million in awards <https://dpcpsi.nih.gov/autism-data-science-initiative/funded-research>will support 13 pioneering projects that draw on genomic, epigenomic, metabolomic, proteomic, clinical, behavioral and autism services data. These projects will integrate, aggregate and analyze existing data resources, generate targeted new data and validate findings through independent replication hubs.Continue reading→